Optimizing antiplatelet / antithrombotic therapy
نویسندگان
چکیده
منابع مشابه
Dual antiplatelet therapy and antithrombotic treatment: Recommendations and controversies.
Dual antiplatelet therapy is currently recommended for all patients with acute coronary syndromes, independent of whether they receive pharmacological treatment or undergo percutaneous coronary intervention. Antiplatelet agents are the cornerstone of pharmacological treatment in interventional cardiology. However, there is a clear need for randomized trials to assess the treatment strategy of d...
متن کاملRegional anaesthesia in the patient receiving antithrombotic and antiplatelet therapy.
The actual incidence of neurological dysfunction resulting from haemorrhagic complications associated with neuraxial block is unknown. Although the incidence cited in the literature is estimated to be <1 in 150,000 epidural and <1 in 220,000 spinal anaesthetics, recent surveys suggest that the frequency is increasing and may be as high as 1 in 3000 in some patient populations. Overall, the risk...
متن کاملNew antithrombotic and antiplatelet treatment.
Thrombosis is the key pathological process in both unstable angina and acute myocardial infarction (MI). Treatment directed against the thrombus may consist of thrombolysis by plasminogen activators, thrombin inhibition, or platelet inhibition. Data from the TIMI IIIA and IIIB trials have shown conclusively that in contrast to their proven benefits in acute MI, plasminogen activators make the p...
متن کاملANTIPLATELET AND ANTITHROMBOTIC THERAPY IN NON ST ELEVATION ACUTE CORONARY SYNDROME: A review of current literature
The most important pathological mechanism in non-ST elevation Acute Coronary Syndrome (ACS) is the formation of a platelet rich thrombus on an atherosclerotic plaque. The understanding of this mechanism has changed the management of ACS with time. Until recently, the combination of aspirin and unfractionated heparin constituted the main antithrombotic therapy in ACS with a 46% reduction in vasc...
متن کاملCurrent antithrombotic treatment in East Asia: some perspectives on anticoagulation and antiplatelet therapy.
Suzuki/2007 (18) Japan NVAF n=667 Target INR value was set at 1.6–2.6 Incidence of major bleeding was 2.38%, which is higher than in Western patients INR ≥2.27 was an independent risk factor for major bleeding NVAF, non-valvular atrial fibrillation; INR, international normalised ratio; d, days. Current antithrombotic treatment in East Asia: Some perspectives on anticoagulation and antiplatelet ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Indian Academy of Neurology
سال: 2010
ISSN: 0972-2327
DOI: 10.4103/0972-2327.70888